DEPO - Testosterone (testosterone cypionate injection) is an androgen indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone including, 1) Primary hypogonadism ( congenital or acquired ) - testicular failure due to cryptorchidism , bilateral torsion, orchitis , vanishing testis syndrome, or orchidectomy; and 2) Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary -hypothalamic injury from tumors, trauma , or radiation . Common side effects of DEPO -Testosterone include:
Testosterone, like many anabolic steroids, was classified as a controlled substance in 1991. Testosterone is administered parenterally in normal and delayed-release (depot) forms. In September 1995, the FDA approved testosterone transdermal patches (Androderm), and many transdermal forms and brands are now available including implants, gels, and topical solutions. A testosterone buccal system, Striant, was FDA-approved in July 2003; Striant is a mucoadhesive product that adheres to the buccal mucosa and provides a controlled and sustained release of testosterone. In May 2014, the FDA approved an intranasal gel formulation of testosterone (Natesto). A transdermal patch (Intrinsa) for hormone replacement in women is under investigation; the daily dosages used in women are much lower than for products used in males. The FDA refused approval for Intrinsa in 2004 stating that more data regarding safety, especially in relation to cardiovascular and breast health, were required.